Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Relapsed or Refractory Leukemia
NCT00083694Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Aug 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in acute leukemia, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL) and 1 more, sponsored by University of Arkansas. Primary endpoints: Efficacy of Thalidomide and Safety of Thalidomide. Started Aug 1998; status: completed.
02
Drugs
thalidomide
03
Conditions
acute leukemiachronic myeloid leukemia (CML)chronic lymphocytic leukemia (CLL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00083694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083694.